USPTO Patent Application for Immunoconjugates

ChangeBridge: Patent Apps - Peptides (C07K)

Published July 11th, 2025

Detected March 26th, 2026

Summary

The USPTO has published a new patent application, US20260083855A1, filed by Hoffmann-La Roche Inc. The application relates to immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. This filing is part of the standard patent application process.

View original document View source feed page

What changed

The United States Patent and Trademark Office (USPTO) has published patent application US20260083855A1, filed on July 11, 2025, by Hoffmann-La Roche Inc. The application details novel immunoconjugates, specifically those combining a mutant interleukin-2 polypeptide with an antibody targeting PD-1. It also covers related polynucleotides, vectors, host cells, production methods, pharmaceutical compositions, and their therapeutic uses, particularly in oncology.

This publication represents a new patent filing and does not impose immediate regulatory obligations on companies. However, it signifies ongoing innovation in the biopharmaceutical sector, particularly in cancer therapeutics. Companies operating in this space, especially those developing similar immunotherapies or antibody-drug conjugates, should be aware of this filing as it may impact future intellectual property landscapes and competitive strategies.

Source document (simplified)

← USPTO Patent Applications

IMMUNOCONJUGATES

Application US20260083855A1 Kind: A1 Mar 26, 2026

Assignee

Hoffmann-La Roche Inc.

Inventors

Laura CODARRI DEAK, Anne FREIMOSER-GRUNDSCHOBER, Ralf Joerg HOSSE, Christian KLEIN, Ekkehard MOESSNER, Valeria GONZALEZ NICOLINI, Pablo UMAÑA FERNÁNDEZ, Inja WALDHAUER

Abstract

The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules encoding the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.